Malvern launches MicroCal PEAQ-DSC for faster, more accurate characterization of protein and biomolecule stability
Supports a wide range of needs across the biopharma development cycle.
The new MicroCal PEAQ-DSC microcalorimeter from Malvern Instruments resets the performance standard for characterizing protein and biomolecule stability. This latest innovation in Differential Scanning Calorimetry (DSC) has been created specifically for the regulated environment and delivers essential data to guide biopharmaceutical development, from protein engineering, through pre-formulation and process development, to formulation and manufacture of the final product.
The new system offers developers a quick stability assay to identify biotherapeutics with good stability potential and enables them to determine the conditions that maximize the shelf-life of a biotherapeutic. In manufacturing, it helps maximize yields of biotherapeutic compounds and supports the robust demonstration of batch-to-batch comparability or innovator to biosimilar comparability.
MicroCal PEAQ-DSC delivers unattended 24-hour operation, together with streamlined workflows and automated data analysis to produce results in hours, driving productivity and efficiency gains in research and production. In addition, the system is network-ready, and has built-in automated cleaning and self-validation protocols that minimize downtime and ensure that all data reported is of the highest quality. Dedicated instrument standards are available so that performance can be validated throughout a series of runs.
Importantly, MicroCal PEAQ-DSC is available with full documentation and software support for Analytical Equipment Qualification, in line with USP and FDA guidance, as well as a comprehensive package to aid technical compliance to FDA CFR Part 11 and EU GMP Annex 11.
Ronan O’Brien, Head of Business Development – MicroCal at Malvern, said: “We are very excited to be putting such a capable tool in the hands of our customers. We have worked closely with users of our previous-generation DSC system to make sure that the MicroCal PEAQ-DSC supports a wide range of needs across the biopharma development cycle. As the importance of biopharmaceuticals continues to grow, we see customers searching for powerful analytical systems that can deliver data that genuinely informs development, formulation and process decisions, as well as supporting regulatory challenges. DSC has long been considered the gold standard for stability measurement but now, with the new MicroCal PEAQ-DSC, we believe we have redefined what is possible with this technique.”
MicroCal PEAQ-DSC is available in two versions: a standalone instrument that includes the DSC cell and a dedicated computer, or a fully automated system with the addition of a liquid handling robot. Either can be specified with the 21 CFR Part 11 software package.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance